Schizophrenia and related disorders during mid- to late-life (R01, R21 Clinical Trial Optional)

Funding Agency:
National Institutes of Health

The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications that will advance translational research to better understand the emergence, trajectory, and outcomes of schizophrenia and related psychotic disorders in mid- to late-life, and to identify targets for future development of prevention and treatment interventions.

This FOA uses the R01 grant mechanism, while the companion FOA (RFA-MH-22-271), uses the R21 mechanism. Investigators proposing high risk/high reward projects that lack preliminary data may be more appropriate for the R21 mechanism.


  • Letter of Intent: 30 days prior to the application due date
  • Application:  Feb. 22, 2023

RFA-MH-22-270 Expiration Date February 23, 2023




Medical - Clinical Science
Medical - Translational

External Deadline

February 22, 2023